Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMN107- NILOTINIB · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| nilotinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AMN107- NILOTINIB | DRUG | The dose of nilotinib will be 400 mg bid. |
Inclusion criteria: * Age ≥ 18 years at Visit 1 * Radiological confirmation of disease progression (CT scan PET-CT, or MRI) during imatinib therapy, on 600- 800 mg per day for at least 6 weeks. * Radiological confirmation of disease progression (CT scan or MRI and PET-CT) during 2nd line TK inhibit...
AMN107, also known as nilotinib, is an investigational small molecule being studied for the treatment of gastrointestinal stromal tumors (GIST). It is specifically being evaluated in patients whose tumors are resistant or intolerant to imatinib and/or a second-line tyrosine kinase inhibitor. The drug is in Phase 2 clinical development.
AMN107, or nilotinib, is a tyrosine kinase inhibitor. It is being studied in gastrointestinal stromal tumors (GIST) that are resistant or intolerant to imatinib and/or a second-line tyrosine kinase inhibitor. The drug works by inhibiting tyrosine kinase enzymes involved in tumor growth.
AMN107, also known as nilotinib, is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is currently in Phase 2 clinical development for gastrointestinal stromal tumors (GIST).
AMN107, also known as nilotinib, is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of gastrointestinal stromal tumors (GIST) that are resistant or intolerant to imatinib and/or a second-line tyrosine kinase inhibitor. It has not been approved by regulatory authorities.
AMN107, also known as nilotinib, has one completed Phase 2 clinical trial registered under NCT00633295. This trial evaluated the efficacy and safety of nilotinib in patients with gastrointestinal stromal tumors (GIST) resistant or intolerant to imatinib and/or a second-line tyrosine kinase inhibitor. The study enrolled 9 participants in Israel.
Yes, AMN107 is the same as nilotinib. The drug is being developed by Novartis AG for the treatment of gastrointestinal stromal tumors (GIST) that are resistant or intolerant to imatinib and/or a second-line tyrosine kinase inhibitor. It is currently in Phase 2 clinical development.